Expansion Of Natural Killer Cells and Efficacy Against Hematologic Malignancies

Authors

  • Jinhan Wu

DOI:

https://doi.org/10.54097/nh8zye69

Keywords:

NK cells; expansion; hematologic malignancies.

Abstract

The battle against cancer in human body relies heavily on natural killer (NK) cells. Therefore, NK cells have been showing great potential in cancer immunotherapy. Adoptive transfer of great amounts of NK cells and their cytotoxicity towards cancer cells are heavily researched because of the fact that the NK cells in patients are typically diminished in quantity and malfunctional because of pretreatment. In this review, we concentrate on the techniques for expanding the four main NK cell sources employed in adoptive cell transfer: peripheral blood, umbilical cord blood, NK cell lines and different types of stem cells. We also investigate the efficacy of NK cells derived from each cell source against hematologic malignancies by analyzing experimental data and propose possible reasons for the discrepancy. In the last part, we touch on the prospect of genetically modified NK cells. We concluded that each cell source has its own advantages and drawbacks in expansion and efficacy. In addition, by combining with cytokines, monoclonal antibodies, and other treatments, the cytotoxicity of NK cells in vivo against hematologic malignancies can be enhanced.

Downloads

Download data is not yet available.

References

Liu S, Galat V, Galat Y, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol, 2021, 14(1):7.

Liu M, Meng Y, Zhang L, et al. X. High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18. Biochem. Biophys. Res. Commun, 2021, 534:149-156.

Reina-Ortiz C, Constantinides M, Fayd-Herbe-de-Maudave A, et al. Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. Oncoimmunology. 2020, 10(1):1853314.

Luevano M, Daryouzeh M, Alnabhan R, et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol, 2012, 73(3):248-57.

Valipour B, Abedelahi A, Naderali E, et al. Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody. Life Sci, 2020, 242:117223.

Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia, 1994, 8(4):652-8.

Nowakowska P, Romanski A, Miller N, et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother., 2018, 67(1):25-38.

Tonn T, Becker S, Esser R, et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res, 2001, 10(4):535-44.

Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol, 2021, 18(2):85-100.

Knorr DA, Ni Z, Hermanson D, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med, 2013, 2(4):274-83.

Cichocki F, Bjordahl R, Gaidarova S, et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Sci Transl Med, 2020, 12(568): eaaz5618.

Woan KV, Kim H, Bjordahl R, et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell, 2021, 28(12):2062-2075.e5.

Downloads

Published

29-12-2023